Search results
Kansas sues Pfizer over 'misrepresentations' and 'adverse events' of COVID-19 vaccine
FOX Business· 2 days agoThe State of Kansas has filed a lawsuit against Pfizer, Inc. for alleged consumer protection...
Moderna says next-generation COVID vaccine efficacy non-inferior to current shot
Reuters via Yahoo News· 7 days agoThe experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people...
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 6 days agoThe company recently reported positive data from the Phase III combination vaccine trial....
Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal
Zacks via Yahoo Finance· 5 days agoData from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved...
Moderna says next-gen COVID shot effective in study
BioPharma Dive via Yahoo Finance· 7 days agoTrial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases...
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Moderna Just Gave Investors Another Reason to Buy the Stock | The Motley Fool
The Motley Fool· 3 days agoModerna (MRNA -3.58%) is best known for its work in the coronavirus vaccine market. Let's look...
Novavax Seeks FDA Nod for Updated COVID-19 Vaccine - Novavax (NASDAQ:NVAX), Moderna (NASDAQ:MRNA)
Benzinga· 1 day agoNovavax's filing is based on guidance from the FDA issued last week, which advised COVID-19 vaccine...
Gateway - Quartz
Quartz· 24 hours agoOnly 22% U.S. adults have received an updated COVID-19 vaccine, according to the Centers for Disease Control and Prevention. Moderna says it managed to ...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation...
The Joplin Globe· 7 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to Spikevax® in participants 12 years of age and older
